It is a novel class of small molecules with the dual mechanism as estrogen receptor antagonist (ER) and degrader. SERDs are a type of hormonal therapy used in the treatment of ER-positive/HER2-negative locally advanced or metastatic breast cancer. They can be employed as monotherapy or in combination with other drugs. SERDs are considered one of the most revolutionary cancer therapies due to their superior clinical profile and ease of administration impacting the quality of life of breast cancer patients positively.

1 Executive Summary 

2 Market Landscape 

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by End-user

7 Market Segmentation by Application

8 Customer Landscape 

9 Geographic Landscape 

10 Drivers, Challenges, and Trends

11 Vendor Landscape 

12 Vendor Analysis